262 related articles for article (PubMed ID: 1982999)
1. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
Carulli G; Petrini M; Marini A; Vaglini F; Caracciolo F; Grassi B
Haematologica; 1990; 75(6):516-21. PubMed ID: 1982999
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
Maslak P; Hegewisch-Becker S; Godfrey L; Andreeff M
Cytometry; 1994 Sep; 17(1):84-93. PubMed ID: 8001461
[TBL] [Abstract][Full Text] [Related]
3. Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide.
Maia RC; Carriço MK; Klumb CE; Noronha H; Coelho AM; Vasconcelos FC; Ruimanek VM
J Exp Clin Cancer Res; 1997 Dec; 16(4):419-24. PubMed ID: 9505216
[TBL] [Abstract][Full Text] [Related]
4. Platelet function in acute leukemias.
Naresh KN; Sivasankaran P; Veliath AJ
J Assoc Physicians India; 1993 Jun; 41(6):377-8. PubMed ID: 8005978
[TBL] [Abstract][Full Text] [Related]
5. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
6. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
7. Interferon production in myelo- and lymphoproliferative diseases. I. Spontaneous interferon production in acute and chronic leukaemias.
Szabó B; Tóth FD; Kiss J; Váczi L; Kiss A; Rák K
Acta Microbiol Hung; 1988; 35(3):295-300. PubMed ID: 2465655
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein in acute nonlymphoblastic leukemia and in the blastic crisis of myeloid leukemia.
Carulli G; Petrini M; Marini A; Ambrogi F
N Engl J Med; 1988 Sep; 319(12):797-8. PubMed ID: 2901038
[No Abstract] [Full Text] [Related]
9. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.
Cavalcanti GB; Vasconcelos FC; Pinto de Faria G; Scheiner MA; de Almeida Dobbin J; Klumb CE; Maia RC
Cytometry B Clin Cytom; 2004 Sep; 61(1):1-8. PubMed ID: 15351976
[TBL] [Abstract][Full Text] [Related]
10. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
11. Selective killing of malignant cells from leukemic patients by alkyl-lysophospholipid.
Verdonck LF; Witteveen EO; van Heugten HG; Rozemuller E; Rijksen G
Cancer Res; 1990 Jul; 50(13):4020-5. PubMed ID: 2354451
[TBL] [Abstract][Full Text] [Related]
12. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias.
Burger H; Nooter K; Zaman GJ; Sonneveld P; van Wingerden KE; Oostrum RG; Stoter G
Leukemia; 1994 Jun; 8(6):990-7. PubMed ID: 7911548
[TBL] [Abstract][Full Text] [Related]
13. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
Derderian PM; Kantarjian HM; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
Am J Med; 1993 Jan; 94(1):69-74. PubMed ID: 8420302
[TBL] [Abstract][Full Text] [Related]
14. [T lymphoblastic leukemia with leukemoid reaction or the extramedullary blast crisis of Philadelphia chromosome-negative chronic myeloid leukemia? Comments apropos 2 cases].
Tassies D; Feliu E; Villamor N; Urbano-Ispizua A; Cervantes F; Campo E; Ordi J; Vernet M; Pujol R; López R
Med Clin (Barc); 1990 Nov; 95(16):618-20. PubMed ID: 2097454
[TBL] [Abstract][Full Text] [Related]
15. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
16. Immunological classification of chronic myeloid leukemia distinguishes chronic phase, imminent blastic transformation, and acute lymphoblastic leukemia.
Schmetzer HM; Gerhartz HH
Exp Hematol; 1997 Jun; 25(6):502-8. PubMed ID: 9197328
[TBL] [Abstract][Full Text] [Related]
17. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot G; Weber G
Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
[TBL] [Abstract][Full Text] [Related]
18. [Undifferentiated blastic cell crisis of chronic myelogenous leukemia with myeloblastic tumor in the skin].
Kawakami K; Kiyosaki M; Amaya H; Nakamaki T; Hino K; Tomoyasu S
Rinsho Ketsueki; 2000 Apr; 41(4):334-40. PubMed ID: 10846465
[TBL] [Abstract][Full Text] [Related]
19. [P-glycoprotein and treatment with plicamycin + hydroxyurea in myeloid blastic crisis of chronic myeloid leukemia].
Carulli G; Marini A; Caracciolo F
Medicina (Firenze); 1989; 9(4):409-10. PubMed ID: 2576761
[TBL] [Abstract][Full Text] [Related]
20. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
